{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:14:03Z","timestamp":1791357243626,"version":"4.3.1"},"update-to":[{"DOI":"10.1002\/14651858.cd011458","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2015,11,24]],"date-time":"2015-11-24T00:00:00Z","timestamp":1448323200000}}],"reference-count":122,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011458.pub2","type":"journal-article","created":{"date-parts":[[2015,11,25]],"date-time":"2015-11-25T05:38:18Z","timestamp":1448429898000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Asenapine versus placebo for schizophrenia"],"prefix":"10.1002","volume":"2015","author":[{"given":"Alistair","family":"Hay","sequence":"first","affiliation":[{"name":"The University of Nottingham; Institute of Mental Health; Jubilee Campus Innovation Park, Triumph Road Nottingham UK NG7 2TU"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Byers","sequence":"additional","affiliation":[{"name":"The University of Nottingham; Institute of Mental Health; Jubilee Campus Innovation Park, Triumph Road Nottingham UK NG7 2TU"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Sereno","sequence":"additional","affiliation":[{"name":"The University of Nottingham; Institute of Mental Health; Jubilee Campus Innovation Park, Triumph Road Nottingham UK NG7 2TU"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manpreet Kaur","family":"Basra","sequence":"additional","affiliation":[{"name":"The University of Nottingham; Institute of Mental Health; Jubilee Campus Innovation Park, Triumph Road Nottingham UK NG7 2TU"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Snigdha","family":"Dutta","sequence":"additional","affiliation":[{"name":"The University of Nottingham; Institute of Mental Health; Jubilee Campus Innovation Park, Triumph Road Nottingham UK NG7 2TU"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,11,24]]},"reference":[{"issue":"11","key":"10.1002\/14651858.CD011458.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1177\/0091270009344855","article-title":"Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongation","volume":"49","author":"Chapel","year":"2009","journal-title":"Journal of Clinical Pharmacology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD011458.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"S453","DOI":"10.1016\/S0924-977X(07)70687-9","article-title":"Effect of asenapine versus quetiapine and placebo on QTc interval in patients with schizophrenia","volume":"17","author":"Preskorn","year":"2007","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0003|cit3","doi-asserted-by":"crossref","unstructured":"Preskorn SH Chapel S Panagides J Effects of asenapine versus placebo on QTc interval in patients with schizophrenia American Psychiatric Association, 161st Annual Meeting, May 3-8, 2008, Washington, DC 2008","DOI":"10.1016\/S0924-977X(07)70687-9"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1111\/j.1742-1241.2009.02228.x","article-title":"Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic","volume":"63","author":"Citrome","year":"2009","journal-title":"The International Journal of Clinical Practice"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.schres.2007.12.026","article-title":"Efficacy and safety of asenapine in patients with acute exacerbation of schizophrenia","volume":"98","author":"Kane","year":"2008","journal-title":"Schizophrenia Research"},{"issue":"2","key":"10.1002\/14651858.CD011458.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/JCP.0b013e3181d35d6b","article-title":"Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia","volume":"30","author":"Kane","year":"2010","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0007|cit7","unstructured":"Kane JM Zhao J Cohen M Panagides J Efficacy and safety of asenapine in patients with acute schizophrenia American Psychiatric Association, 161st Annual Meeting, May 3-8, 2008, Washington, DC 2008"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0008|cit8","unstructured":"NCT00156104 A multicenter, randomized, double-blind, fixed-dose, 6-week trial of the efficacy and safety of asenapine compared with placebo using haloperidol positive control in subjects with an acute exacerbation of schizophrenia http:\/\/clinicaltrials.gov\/show\/NCT00156104 2008"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0009|cit9","doi-asserted-by":"crossref","unstructured":"Potkin SG Kane JM Emsley RA Naber D Panagides J Asenapine in schizophrenia: an overview of clinical trials in the Olympia program Society of Biological Psychiatry, 63rd Annual Scientific Convention and Meeting, May 1-3, 2008, Washington, DC 2008","DOI":"10.1016\/S0920-9964(08)70778-3"},{"issue":"3","key":"10.1002\/14651858.CD011458.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4088\/JCP.10m06306","article-title":"A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment","volume":"72","author":"Kane","year":"2011","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0011|cit11","first-page":"223","article-title":"Double-blind, placebo-controlled trial of asenapine in prevention of relapse after long-term treatment of schizophrenia","volume":"13","author":"Kane","year":"2010","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0012|cit12","doi-asserted-by":"crossref","unstructured":"Mackle M Snow-Adami L Zhao J Szegedi A Panagides J Double-blind, placebo-controlled trial of asenapine in prevention of relapse after long-term treatment of schizophrenia European Neuropsychopharmacology 2009 pp S543","DOI":"10.1016\/S0924-977X(09)70864-8"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0013|cit13","unstructured":"NCT00150176 A randomized, placebo-controlled, double-blind trial of asenapine in the prevention of relapse after long-term treatment of schizophrenia http:\/\/clinicaltrials.gov\/show\/NCT00150176 2005"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1111\/j.1742-1241.2009.02228.x","article-title":"Asenapine for schizophrenia and bipolar disorder: A review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic","volume":"63","author":"Citrome","year":"2009","journal-title":"The International Journal of Clinical Practice"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0015|cit15","unstructured":"NCT00151424 A multicenter, randomized, double-blind, flexible-dose, 6-week trial of the efficacy and safety of asenapine compared with placebo using olanzapine positive control in subjects with an acute exacerbation of schizophrenia http:\/\/clinicaltrials.gov\/show\/NCT00151424 2005"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0016|cit16","doi-asserted-by":"crossref","unstructured":"Potkin SG Kane JM Emsley RA Naber D Panagides J Asenapine in schizophrenia: an overview of clinical trials in the Olympia program Society of Biological Psychiatry, 63rd Annual Scientific Convention and Meeting, May 1-3, 2008, Washington, DC 2008","DOI":"10.1016\/S0920-9964(08)70778-3"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.4088\/JCP.11r07596","article-title":"Meta-analyses of the efficacy of asenapine for acute schizophrenia: comparisons with placebo and other antipsychotics","volume":"73","author":"Szegedi","year":"2012","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1111\/j.1742-1241.2009.02228.x","article-title":"Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic","volume":"63","author":"Citrome","year":"2009","journal-title":"The International Journal of Clinical Practice"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0019|cit19","doi-asserted-by":"crossref","unstructured":"Leucht S Zhao J Early improvement as a predictor of treatment response and remission in patients with acute schizophrenia: effects of asenapine European Neuropsychopharmacology 2013 S470","DOI":"10.1016\/S0924-977X(13)70744-2"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1177\/0269881113517956","article-title":"Early improvement as a predictor of treatment response and remission in patients with schizophrenia: a pooled, post-hoc analysis from the asenapine development program","volume":"28","author":"Leucht","year":"2014","journal-title":"Journal of Psychopharmacology"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0021|cit21","unstructured":"NCT00156117 A multicenter, randomized, double-blind, fixed-dose, 6-week trial of the efficacy and safety of asenapine compared with placebo using olanzapine positive control in subjects with an acute exacerbation of schizophrenia http:\/\/clinicaltrials.gov\/show\/NCT00156117 2005"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0022|cit22","doi-asserted-by":"crossref","unstructured":"Potkin SG Kane JM Emsley RA Naber D Panagides J Asenapine in schizophrenia: an overview of clinical trials in the Olympia program Society of Biological Psychiatry, 63rd Annual Scientific Convention and Meeting, May 1-3, 2008, Washington, DC 2008","DOI":"10.1016\/S0920-9964(08)70778-3"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.4088\/JCP.11r07596","article-title":"Meta-analyses of the efficacy of asenapine for acute schizophrenia: comparisons with placebo and other antipsychotics","volume":"73","author":"Szegedi","year":"2012","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1111\/j.1742-1241.2009.02228.x","article-title":"Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic","volume":"63","author":"Citrome","year":"2009","journal-title":"The International Journal of Clinical Practice"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD011458.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"S466","DOI":"10.1016\/S0924-977X(07)70710-1","article-title":"Effects of asenapine on cognitive function in acute schizophrenia: a placebo- and risperidone-controlled trial","volume":"17","author":"Fleming","year":"2007","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0026|cit26","unstructured":"Potkin S Fleming K Binneman B Keller DS Alphs L Panagides J Asenapine improves cognitive function in acute schizophrenia: a placebo- and risperidone- controlled trial Proceedings of the 160th Annual Meeting of the American Psychiatric Association; 2007 May 19-24; San Diego, CA 2007"},{"issue":"2","key":"10.1002\/14651858.CD011458.pub2-BIB0027|cit27","first-page":"454","article-title":"Asenapine cognitive function effects in acute schizophrenia: a placebo-and risperidone-controlled trial","volume":"33","author":"Potkin","year":"2007","journal-title":"Schizophrenia Bulletin"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011458.pub2-BIB0028|cit28","first-page":"S112","article-title":"Asenapine, a novel psychotherapeutic agent with efficacy in positive and negative symptoms during acute episodes of schizophrenia: a randomized, placebo- and risperidone-controlled trial","volume":"30","author":"Potkin","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0029|cit29","unstructured":"Potkin SG Cohen M Jina AS Nettler S Alphs L Panagides J Asenapine efficacy during acute episodes of schizophrenia: a randomized placebo and risperidone controlled trial Proceedings of the 44th Annual Meeting of the American College of Neuro-Psychopharmacology; 2005 Dec 11-15; Waikoloa, Hawaii 2005"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0030|cit30","unstructured":"Potkin SG Cohen M Jina AS Nettler S Alphs L Panagides J Asenapine efficacy during acute episodes of schizophrenia: a randomized placebo- and risperidone-controlled trial 13th Biennial Winter Workshop on Schizophrenia Research, February 4-10, 2006, Davos, Switzerland 2006"},{"issue":"10","key":"10.1002\/14651858.CD011458.pub2-BIB0035|cit31","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.4088\/JCP.v68n1004","article-title":"Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial","volume":"68","author":"Potkin","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD011458.pub2-BIB0031|cit32","doi-asserted-by":"crossref","first-page":"S401","DOI":"10.1016\/S0924-977X(06)70497-7","article-title":"Asenapine safety and tolerability in acute schizophrenia: a placebo- and risperidone-controlled trial","volume":"16","author":"Potkin","year":"2006","journal-title":"European Neuropsychopharmacology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011458.pub2-BIB0032|cit33","first-page":"S275","article-title":"Asenapine efficacy in acute schizophrenia: a randomized, placebo- and risperidone-controlled trial","volume":"9","author":"Potkin","year":"2006","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"8 Suppl","key":"10.1002\/14651858.CD011458.pub2-BIB0033|cit34","first-page":"154S","article-title":"Asenapine efficacy, safety, and tolerability in the treatment of acute schizophrenia: a randomized, placebo- and risperidone-controlled trial","volume":"59","author":"Potkin","year":"2006","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0034|cit35","unstructured":"Potkin SG Cohen M Panagides J Jina AS Asenapine safety and tolerability during acute schizophrenia: a placebo- and risperidone controlled trial Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25, Toronto, Canada 2006"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0036|cit36","doi-asserted-by":"crossref","unstructured":"Potkin SG Kane JM Emsley RA Naber D Panagides J Asenapine in schizophrenia: an overview of clinical trials in the Olympia program Society of Biological Psychiatry, 63rd Annual Scientific Convention and Meeting, May 1-3, 2008, Washington, DC 2008","DOI":"10.1016\/S0920-9964(08)70778-3"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0037|cit37","unstructured":"Castle D Jensen JKS Management of depressive symptoms in schizophrenia: a pooled, post hoc analysis from the asenapine development program (Manuscript submitted for peer-review, journal not currently known)"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"S502","DOI":"10.1016\/S0924-977X(13)70797-1","article-title":"Management of depressive symptoms in schizophrenia: a pooled, post hoc analysis from the asenapine development program","volume":"23","author":"Castle","year":"2013","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0040|cit39","unstructured":"Cazorla P Panagides J Alphs L Kouassi A Buchanan R Asenapine versus olanzapine in patients with predominant, persistent negative symptoms of schizophrenia American Psychiatric Association, 161st Annual Meeting, May 3-8, 2008, Washington, DC 2008"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011458.pub2-BIB0039|cit40","first-page":"138","article-title":"Asenapine versus olanzapine in patients with predominant, persistent negative symptoms of schizophrenia","volume":"11","author":"Cazorla","year":"2008","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"S536","DOI":"10.1016\/S0924-977X(09)70853-3","article-title":"Long-term safety and maintenance of effect of asenapine in patients with acute exacerbation of schizophrenia","volume":"19","author":"Meltzer","year":"2009","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0042|cit42","unstructured":"NCT00156065 A multicenter, double-blind, flexible dose, long-term extension trial of the safety and maintenance of effect of asenapine using a haloperidol positive control in subjects who complete protocol 041023 http:\/\/clinicaltrials.gov\/show\/NCT00156065 2005"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0043|cit43","unstructured":"NCT01142596 Long-term extension trial of asenapine in subjects with schizophrenia (study p06125) http:\/\/clinicaltrials.gov\/show\/NCT01142596 2010"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0044|cit44","unstructured":"NCT01190254 Fixed dose efficacy and safety study of asenapine for the treatment of schizophrenia in adolescents (study p05896) http:\/\/clinicaltrials.gov\/show\/NCT01190254 2010"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0045|cit45","unstructured":"The National Horizon Scanning Centre Asenapine (Saphris) for schizophrenia The National Horizon Scanning Centre, Department of Public Health and Epidemiology, University of Birmingham 2010"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0046|cit46","unstructured":"NCT00156091 A multicenter, double-blind, flexible-dose, long-term extension trial of the safety and maintenance of effect of asenapine using olanzapine positive control in subjects who complete protocols 041021\/041022 http:\/\/clinicaltrials.gov\/show\/NCT00156091 2005"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0047|cit47","unstructured":"Nct 6-week trial of the efficacy and safety of asenapine compared to placebo in subjects with an acute exacerbation of schizophrenia (Study P06124) http:\/\/clinicaltrials.gov\/show\/NCT01098110 2010"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0048|cit48","unstructured":"NCT01617187 A study of the efficacy and safety of asenapine in participants with an acute exacerbation of schizophrenia (p05688 am2) http:\/\/clinicaltrials.gov\/show\/NCT01617187 2012"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1017\/S1461145704004110","article-title":"Do we still believe in the dopamine hypothesis? New data bring new evidence","volume":"7","author":"Abi-Dargham","year":"2004","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"11","key":"10.1002\/14651858.CD011458.pub2-BIB0050|cit50","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003082.pub3","article-title":"Haloperidol versus placebo for schizophrenia","author":"Adams","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1192\/S0007125000292581","article-title":"Assessing depression in schizophrenia: the Calgary Depression Scale","volume":"163","author":"Addington","year":"1993","journal-title":"The British Journal of Psychiatry"},{"issue":"7066","key":"10.1002\/14651858.CD011458.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/archpsyc.56.9.781","article-title":"A unitary model of schizophrenia. Bleuler's \"fragmented phrene\" as schizencephaly","volume":"56","author":"Andreasen","year":"1999","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0054|cit54","unstructured":"Ayuso-Mateos JL Global burden of schizophrenia in the year 2000 http:\/\/www.who.int\/healthinfo\/statistics\/bod_schizophrenia.pdf 2006"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"The British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0056|cit56","first-page":"483","article-title":"Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar I disorder","volume":"5","author":"Bishara","year":"2009","journal-title":"Neuropsychiatric Disease and Treatment"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD011458.pub2-BIB0058|cit58","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Th\u00e9rapie"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1046\/j.1365-2125.1999.00849.x","article-title":"The use of atypical antipsychotics in the management of schizophrenia","volume":"47","author":"Campbell","year":"1999","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1111\/j.1742-1241.2009.02228.x","article-title":"Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic","volume":"63","author":"Citrome","year":"2009","journal-title":"The International Journal of Clinical Practice"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1136\/bmj.280.6207.66","article-title":"Molecular pathology of schizophrenia: more than one disease process?","volume":"280","author":"Crow","year":"1980","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archpsyc.60.6.553","article-title":"A meta-analysis of the efficacy of second-generation antipsychotics","volume":"60","author":"Davis","year":"2003","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0063|cit63","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town Cape Town The Cochrane Collaboration 2000"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0064|cit64","unstructured":"Deeks JJ Higgins JPT Altman DG (editors) Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"6","key":"10.1002\/14651858.CD011458.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"2","key":"10.1002\/14651858.CD011458.pub2-BIB0067|cit67","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001359.pub2","article-title":"Olanzapine for schizophrenia","author":"Duggan","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD011458.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0070|cit70","unstructured":"European Medicines Agency Sycrest: EPAR - Product information http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/001177\/WC500096895.pdf 2014"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.schres.2013.09.008","article-title":"Is the ongoing use of placebo in relapse-prevention clinical trials in schizophrenia justified?","volume":"150","author":"Emsley","year":"2013","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0072|cit72","unstructured":"Food Drug Administration Saphris (asenapine) prescribing information http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/022117s012lbl.pdf 2013"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s11065-005-6254-9","article-title":"A meta-analysis of cognitive deficits in adults with a diagnosis of schizophrenia","volume":"15","author":"Fioravanti","year":"2005","journal-title":"Neuropsychology Review"},{"issue":"7","key":"10.1002\/14651858.CD011458.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0076|cit76","volume-title":"ECDEU Asessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.tips.2004.07.002","article-title":"Functional, molecular and pharmacological advances in 5-HT7 receptor research","volume":"25","author":"Hedlund","year":"2004","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0079|cit79","unstructured":"Higgins JPT Deeks JJ (editors) Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org."},{"key":"10.1002\/14651858.CD011458.pub2-BIB0080|cit80","unstructured":"Higgins JPT Altman DG Sterne JAC (editors) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0081|cit81","unstructured":"Higgins JPT Deeks JJ Altman DG (editors) Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org"},{"issue":"1","key":"10.1002\/14651858.CD011458.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2141.2009.07707.x","article-title":"Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials","volume":"146","author":"Hutton","year":"2009","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0083|cit83","volume-title":"Positive and Negative Syndrome Scale (PANSS) Manual","author":"Kay","year":"1986"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s00127-007-0171-6","article-title":"Psychosis risk as a function of age at onset","volume":"4","author":"Kohler","year":"2007","journal-title":"Social Psychiatry and Psychiatric Epidemiology"},{"issue":"11","key":"10.1002\/14651858.CD011458.pub2-BIB0086|cit86","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010230","article-title":"Asenapine versus typical antipsychotics for schizophrenia","author":"Kumar","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD011458.pub2-BIB0087|cit87","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009935","article-title":"Quetiapine versus placebo for schizophrenia","author":"Lankappa","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1177\/070674379704200205","article-title":"The history of the psychopharmacology of schizophrenia","volume":"42","author":"Lehmann","year":"1997","journal-title":"Canadian Journal of Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD011458.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.biopsych.2005.10.020","article-title":"Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology","volume":"59","author":"Leon","year":"2006","journal-title":"Biological Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD011458.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0091|cit91","doi-asserted-by":"crossref","unstructured":"Leucht S Zhao J Early improvement as a predictor of treatment response and remission in patients with acute schizophrenia: effects of asenapine European Neuropsychopharmacology 2013 S470","DOI":"10.1016\/S0924-977X(13)70744-2"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1177\/0269881113517956","article-title":"Early improvement as a predictor of treatment response and remission in patients with schizophrenia: a pooled, post-hoc analysis from the asenapine development program","volume":"28","author":"Leucht","year":"2014","journal-title":"Journal of Psychopharmacology"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1192\/bjp.151.2.145","article-title":"The symptoms of chronic schizophrenia. A re-examination of the positive-negative dichotomy","volume":"151","author":"Liddle","year":"1987","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0094|cit94","first-page":"20","article-title":"Managing anticholinergic side effects","volume":"6","author":"Lieberman","year":"2004","journal-title":"The Primary Care Companion to the Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4088\/JCP.v58n1205","article-title":"The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: Combined results of the North American trials","volume":"58","author":"Marder","year":"1997","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/epirev\/mxn001","article-title":"Schizophrenia: a concise overview of incidence, prevalence, and mortality","volume":"30","author":"McGrath","year":"2008","journal-title":"Epidemiological Reviews"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"106S","DOI":"10.1016\/S0893-133X(99)00046-9","article-title":"The role of serotonin in antipsychotic drug action","volume":"21","author":"Meltzer","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"c869","DOI":"10.1136\/bmj.c869","article-title":"CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Moher","year":"2010","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0100|cit100","first-page":"617","article-title":"Adverse effects of antipsychotic medications","volume":"81","author":"Muench","year":"2010","journal-title":"American Family Physician"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0101|cit101","first-page":"1172","article-title":"How to examine patients using the Abnormal Involuntary Movement Scale","volume":"39","author":"Munetz","year":"1988","journal-title":"Hospital & Community Psychiatry"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0140-6736(83)90185-X","article-title":"Antihistamines and sedation","volume":"322","author":"Nicholson","year":"1983","journal-title":"The Lancet"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"issue":"12","key":"10.1002\/14651858.CD011458.pub2-BIB0104|cit104","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008902","article-title":"Asenapine versus other atypical antipsychotics for schizophrenia","author":"Preda","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD011458.pub2-BIB0105|cit105","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006918.pub2","article-title":"Risperidone versus placebo for schizophrenia","author":"Rattehalli Ranganath","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"0413","DOI":"10.1371\/journal.pmed.0020141","article-title":"A systematic review of the prevalence of schizophrenia","volume":"2","author":"Saha","year":"2005","journal-title":"PLoS Medicine"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0107|cit107","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JPT Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org 2011"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/0269881107082944","article-title":"Asenapine: a novel psychopharmacologic agent with a unique human receptor signature","volume":"23","author":"Shahid","year":"2009","journal-title":"Journal of Psychopharmacology"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"45","author":"Simpson","year":"1970","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1176\/appi.ajp.157.9.1379","article-title":"Depression in schizophrenia: perspective in the era of \"atypical\" antipsychotic agents","volume":"157","author":"Siris","year":"2000","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0111|cit111","unstructured":"Sterne JAC Egger M Moher D (editors) Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.clinthera.2012.03.002","article-title":"Asenapine: a clinical review of a second-generation antipsychotic","volume":"34","author":"Stoner","year":"2012","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0924-977X(97)00081-3","article-title":"Schizophrenia: do we really need placebo-controlled studies?","volume":"8","author":"Storosum","year":"1998","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.pnpbp.2003.09.009","article-title":"a-Adrenoceptor modulation hypothesis of antipsychotic atypicality","volume":"27","author":"Svensson","year":"2003","journal-title":"Progress in Neuro-Psychopharmacology & Biological Psychiatry"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0115|cit115","unstructured":"Sycrest Sycrest patient information leaflet http:\/\/www.sycrest.co.uk\/siteuploads\/PIL.pdf 2014"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.4088\/JCP.11r07596","article-title":"Meta-analyses of the efficacy of asenapine for acute schizophrenia: Comparisons with placebo and other antipsychotics","volume":"73","author":"Szegedi","year":"2012","journal-title":"Journal of Clinical Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD011458.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1093\/schbul\/sbn117","article-title":"Gene-environment interactions in schizophrenia: review of epidemiological findings and future directions","volume":"34","author":"Os","year":"2008","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1146\/annurev.psych.55.090902.141950","article-title":"Schizophrenia: etiology and course","volume":"55","author":"Walker","year":"2004","journal-title":"Annual Review of Psychology"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0120|cit120","unstructured":"World Health Organization Schizophrenia http:\/\/www.who.int\/mental_health\/management\/schizophrenia\/en\/ 2014"},{"key":"10.1002\/14651858.CD011458.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1093\/ajhp\/57.3.238","article-title":"Atypical antipsychotic agents: a critical review","volume":"57","author":"Worrel","year":"2000","journal-title":"American Journal of Health-System Pharmacy"},{"issue":"7","key":"10.1002\/14651858.CD011458.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1192\/pb.bp.108.021949","article-title":"Loss to outcomes stakeholder survey: the LOSS study","volume":"33","author":"Xia","year":"2009","journal-title":"Psychiatric Bulletin"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD011458.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T10:03:06Z","timestamp":1647165786000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD011458.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,11,24]]},"references-count":122,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2015,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011458.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,24]]}}}